SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 17,250,000 shares of its common stock, including 2,250,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of

bonyf NV announces its participation at ExpoPharm 2025, one of Europe’s largest pharmaceutical trade fairs, held in Düsseldorf from 16 to 18 September 2025. bonyf NV (ENX.PA:MLBON) We are delighted to participate at ExpoPharm, presenting our latest products to healthcare professionals. Our focus on innovation enables us to bring real solutions that improve patients’ daily lives.” — Jean-Pierre Bogaert, CEO of bonyf KNOKKE-HEIST, KNOKKE-HEIST, BELGIUM, September 15, 2025 / EINPresswire.com / -- b

COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement Summary Company Announcement Date: September 12, 2025 FDA Publish Date: September 15, 2025 Product Type: Medical Devices Reason for Announcement: Recall Reason Description Pump performance variations compared to the performance described in the user manual could impact in

Catalog Catalog# Description UDI-DI 1000911 t:slim X2 GS, Replacement, Refurbished 00853052007318 1003808 t:slim X2 GS Classic, Replacement, Refurbished 00853052007981 1004219 t:slim X2, Basal-IQ, mg/dl 00853052007998 1004484 Pump, t:slim X2, Clinical Use Only N/A 1005611 Pump, t:slim X2, Control-IQ, mmol/L 00850006613304 1005613 Pump, t:slim X2, Control-IQ, mmol/L, Refurbished Replacement 00850006613311 1005615 Pump, t:slim X2, Control-IQ, mg/dl 00850006613328 1005617 Pump, t:slim X2, Control-I

BALA CYNWYD, PA, UNITED STATES, September 15, 2025 / EINPresswire.com / -- Sleep Specialist, LLC (DBA 2Z Medical) today announced that more than 2,000 board-certified sleep medicine physicians across the United States have now prescribed Zzoma ยฎ for patients with positional obstructive sleep apnea (POSA). This milestone corresponds to over 25% of all U.S. sleep medicine specialists, underscoring Zzomaโ€™ s widespread adoption as a clinically proven and patient-friendly alternative to CPAP. Zzom

Collaborative Team Earns Five-Year Renewal Grant from NINDS to Continue Stroke Research Our long-term goal is to translate the lead Nln activators from bench to bedside and develop an effective stroke therapy, which could transform the current treatment modalities for patients.” — Dr. Thomas Abbruscato, director of Brain Drug Discovery Research Center LUBBOCK, TX, UNITED STATES, September 15, 2025 / EINPresswire.com / -- Stroke research aims to understand the brain’s self-protective and repair m

The Brookbush Institute continues to enhance education with new courses, a modern glossary, an AI Tutor, and a client program generator. Cohort studies provide stronger evidence of causation than many observational designs by establishing temporal sequence, but they still cannot fully eliminate confounders or prove the effect mechanism” — Dr. Brent Brookbush, CEO of Brookbush Institute NEW YORK, NY, UNITED STATES, September 15, 2025 / EINPresswire.com / -- - Excerpt from Glossary Term: Cohort St

Speech by Grace Graham Deputy Commissioner for Policy, Legislation, and International Affairs - Food and Drug Administration Good afternoon. On behalf of the FDA, I am pleased to welcome you to the sixth Online Controlled Substances Summit. Thank you for the introduction, Susan, and thanks to the Reagan-Udall Foundation and the FDA team for your efforts in convening this Summit. And to our speakers, panelists, and attendees, thank you for taking the time to participate in what should be an impo

Integration of Deepcell's REM-I will enable high-dimensional, label-free single cell analysis and sorting to accelerate InGel’s therapeutic development pipeline Deepcell’s REM-I platform gives us the ability to interrogate single cells in new ways, helping us accelerate our progress toward therapies that can change lives.” — Deepti Singh, PhD, Co-founder & CSO of InGel Therapeutics MENLO PARK, CA, UNITED STATES, September 15, 2025 / EINPresswire.com / -- Deepcell , a pioneer in AI-powered, label

SANTA ANA, Calif., Sept. 15, 2025 /PRNewswire/ -- Today, Autonomous Medical Devices Incorporated (AMDI) announced its submission to the US Food and Drug Administration (FDA) of a dual 510(k) and CLIA Waiver application for the AMDI™ Fast PCR Mini Respiratory Panel and AMDI™ Fast PCR Instrument. The Fast PCR Mini Respiratory Panel is a multiplexed RT-PCR test for the simultaneous detection of Flu A, Flu B, RSV, and SARS-CoV-2 directly from an anterior nasal swab specimen with a sample to answer t